Supplementary Data 2 from Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER⁺ Breast Cancer Models

• DOI: 10.1158/1078-0432.26711142.v1
• Publication Date: 2024-08-15T07:30:46Z
• Authors: Sheryl M. Gough; John J. Flanagan; Jessica Teh; Monica Andreoli; Emma Rousseau; Melissa Pannone; Mark Bookbinder; Ryan Willard; Kim Davenport; Elizabeth Bortolon; Gregory Cadelina; Debbie Gordon; Jennifer Pizzano; Jennifer Macaluso; Leofal Soto; John Corradi; Katherine Digiana...; Ieva Drulyte; Alicia Morgan; Connor Quinn; Miklós Békés; Caterina Ferraro; Xin Chen; Gan Wang; Hanqing Dong; Jing Wang; David R. Langley; John Houston; Richard Gedrich; Ian C. Taylor

<p>Supplementary Tables S1-S4 and Figures S1-S16</p>